SCHEMBL1663673

SCHEMBL1663673

CCCc1c(O)ccc2c(=O)n(-c3ccc(C#N)cc3)c(C(C)C)nc12

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.58
CXCR3 P49682 10/20 0.43
PDE10A Q9Y233 1/20 0.39
ESR1 P03372 2/20 0.39
ESR2 Q92731 2/20 0.39
ALDH1A2 O94788 1/20 0.36
ALDH1A3 P47895 1/20 0.36
USP14 P54578 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP1A2 P05177 1/20 0.34
GLA P06280 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
HPGD P15428 1/20 0.34
CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10446190 0.92 TRPV1 (0.60) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL1663348 0.89 TRPV1 (0.60) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL11931943 0.87 TRPV1 (0.53) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL15957757 0.87 RAB9A (0.42) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL1663563 0.87 TRPV1 (0.60) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL10445926 0.86 ESR1 (0.41) TRPV1PDE10AESR1ESR2KDM4E
SCHEMBL10446186 0.84 TRPV1 (0.64) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL1663494 0.83 TRPV1 (0.62) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL1663854 0.82 TRPV1 (0.57) TRPV1CXCR3PDE10AESR1ESR2
SCHEMBL10446284 0.82 TRPV1 (0.57) TRPV1CXCR3PDE10AESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885CXCR3 312/4885PDE10A 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.